Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

Filter by

Journal of pain and symptom management

Patient-Reported Quality Measures for Palliative Care: The Time is now.

2022

Authors: Walling AM, Ast K, Harrison JM, Dy SM, Ersek M, Hanson LC, Kamal AH, Ritchie CS, Teno JM, Rotella JD, Periyakoil VS, Ahluwalia SC

Breast (Edinburgh, Scotland)

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor?positive/human epidermal growth factor receptor 2?negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.

2022

Authors: Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Di?ras V

Contemporary clinical trials

Optimizing intervention tools to improve nutrition and physical activity for colorectal cancer survivors (Tools To Be Fit): Study protocol of a randomized factorial experiment.

2022

Authors: Kenfield SA, Philip EJ, Phillips SM, Meyerhardt JA, Chan JM, Atreya CE, Kim MO, Harris Q, Steiding P, Macaire G, McCullough ML, Piawah S, Johnson WY, Kurttila FA, Lewis WL, Pesmen C, Watson Y, Van Blarigan EL

World neurosurgery

Mutational status and clinical outcomes following systemic therapy with or without focal radiation for resected melanoma brain metastases.

2022

Authors: Vasudevan HN, Susko MS, Ma L, Nakamura JL, Raleigh DR, Boreta L, Fogh S, Theodosopoulos PV, McDermott MW, Tsai KK, Sneed PK, Braunstein SE

Blood

Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants.

2022

Authors: Andrew H. Tam, Aaron C. Logan, Angela J. Choi, Richard Fong, Lloyd E. Damon, Rebecca L. Olin, Neil Dunavin, Peter H. Sayre, Karin L. Gaensler, Catherine Smith, Lily Yan

Chest

Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.

2022

Authors: Fortis S, Quibrera PM, Comellas AP, Bhat SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB, Subpopulations and Intermediate Outcome Measures in COPD Study Investigators

International journal of prisoner health

Increasing availability of COVID-19 vaccine to older adults under community supervision.

2022

Authors: Dauria E, Clemenzi-Allen A, Nowotny K, Brinkley-Rubinstein L, Williams B, Wurcel A

JCO oncology practice

Impact of a Comprehensive Financial Resource on Financial Toxicity in a National, Multiethnic Sample of Adult, Adolescent/Young Adult, and Pediatric Patients With Cancer.

2022

Authors: Ragavan MV, Mora RV, Winder K, Incudine A, Cunningham R, Stivers T, Borno HT

López L. Patient Experiences and Health Care Quality for Veterans in VHA by Race/Ethnicity. In: Washington DL (ed). National Veteran Health Equity Report 2021. Focus on Veterans Health Administration Patient Experience and Health Care Quality. Washington

López L. Patient Experiences and Health Care Quality for Veterans in VHA by Race/Ethnicity. In: Washington DL (ed). National Veteran Health Equity Report 2021. Focus on Veterans Health Administration Patient Experience and Health Care Quality. Washington

2022

Authors:

Volume 57 of Issue 8 | The Annals of pharmacotherapy

Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19.

2022

Authors: Hess R, Renner E, Mouland E, Sutter-Long D, Ha N

View Abstract

BACKGROUND

Warfarin, a commonly prescribed anticoagulant, requires frequent lab monitoring. Lab monitoring puts patients at risk of COVID-19 exposure and diverts medical resources away from health care systems. Direct oral anticoagulants (DOACs) do not require routine therapeutic monitoring and are indicated first line for nonvalvular atrial fibrillation (NVAF) stroke prevention and venous thromboembolism (VTE) prevention/treatment.

OBJECTIVE

The purpose of the study was to determine the proportion of patients who qualify for DOACs and assess for predictors of qualification.

METHODS

This cross-sectional study investigated patients on warfarin managed by Michigan Medicine Anticoagulation Service. Direct oral anticoagulant eligibility criteria were established using apixaban, dabigatran, and rivaroxaban package inserts. Patient eligibility was determined through chart review. The primary outcome was the proportion of patients who qualify for DOACs based on clinical factors. Predictors of DOAC qualification were assessed.

RESULTS

This study included 3205 patients and found 51.8% ( = 1661) of patients qualified for DOACs. Qualifying patients were older (71.9 vs 59.4 years, < 0.0001) with a higher CHADS VASc (3.7 vs 3.4, < 0.0007). The primary disqualifying factor was extreme weight, high and low. Accounting for a patient's sex and referral source, age > 65 (odds ratio [OR] = 1.9, < 0.0001) and NVAF indication (OR = 5.6, < 0.0001) were significant predictors for DOAC qualification.

CONCLUSION AND RELEVANCE

Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.

View on PubMed